• Profile

Baseline serum biomarkers of inflammation, bone turnover and adipokines predict spinal radiographic progression in ankylosing spondylitis patients on TNF inhibitor therapy

Seminars in Arthritis and Rheumatism Feb 05, 2022

In patients receiving TNF-α inhibitors (TNFi) for ankylosing spondylitis (AS), serum levels of biomarkers at baseline can predict radiographic spinal progression over 2 and 4 years, independent of recognized risk factors.

  • This study included 137 AS patients from the Groningen Leeuwarden Axial Spondyloarthritis (GLAS) cohort before starting TNFi, and serum biomarkers were assessed at baseline, 3 months and 2 years.

  • Baseline calprotectin and visfatin concentrations were found to be linked with mSASSS progression ≥2 points (OR 1.195 and 1.465, respectively), while calprotectin was also identified to be linked with new syndesmophyte formation after 2 years (OR 1.107).

  • Progression of mSASSS ≥4 points after 4 years was related to baseline leptin level (OR 0.614), and baseline sCTX (serum C-terminal telopeptide fragments of type I collagen) level was associated with syndesmophyte formation post-4 years (OR 1.004).

  • Furthermore, alteration of visfatin and leptin concentrations over the first 2 years demonstrated significant link with radiographic progression following 4 years.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen